<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35334101</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1933-7205</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Reproductive sciences (Thousand Oaks, Calif.)</Title>
          <ISOAbbreviation>Reprod Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Exosome-Mediated Transfer of miR-1323 from Cancer-Associated Fibroblasts Confers Radioresistance of C33A Cells by Targeting PABPN1 and Activating Wnt/β-Catenin Signaling Pathway in Cervical Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>1809</StartPage>
          <EndPage>1821</EndPage>
          <MedlinePgn>1809-1821</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s43032-021-00820-y</ELocationID>
        <Abstract>
          <AbstractText>Plenty of pieces of evidence suggest that the resistance to radiotherapy greatly influences the therapeutic effect in cervical cancer (CCa). MicroRNAs (miRNAs) have been reported to regulate cellular processes by acting as tumor suppressors or promoters, thereby driving radioresistance or radiosensitivity. Meanwhile, it has been reported that microRNA-1323 (miR-1323) widely participates in cancer progression and radiotherapy effects. However, the role of miR-1323 is still not clear in CCa. Hence, in this study, we are going to investigate the molecular mechanism of miR-1323 in CCa cells. In the beginning, miR-1323 was found aberrantly upregulated in CCa cells via RT-qPCR assay. Functional assays indicated that miR-1323 was transferred by cancer-associated fibroblasts-secreted (CAFs-secreted) exosomes and miR-1323 downregulation suppressed cell proliferation, migration, invasion, and increased cell radiosensitivity in CCa. Mechanism assays demonstrated that miR-1323 targeted poly(A)-binding protein nuclear 1 (PABPN1). Besides, PABPN1 recruited insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) to regulate glycogen synthase kinase 3 beta (GSK-3β) and influenced Wnt/β-catenin signaling pathway. Therefore, rescue experiments were implemented to validate that PABPN1 overexpression rescued the inhibited cancer development and radioresistance induced by the miR-1323 inhibitor. In conclusion, miR-1323 was involved in CCa progression and radioresistance which might provide a novel insight for CCa treatment.</AbstractText>
          <CopyrightInformation>© 2022. Society for Reproductive Investigation.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0003-0650-398X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Obsterics, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuchang District, Wuhan, 430060, Hubei, China. fangai79197327245@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Chunfeng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, the First Affiliated Hospital of Xinjiang Medical University, Urumchi, 830054, Xinjianag, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Weinan</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Human Anatomy and Embrylogy, Chengdu Medical College, Chengdu, 610083, Sichuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Obsterics, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuchang District, Wuhan, 430060, Hubei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Limei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Reprod Sci</MedlineTA>
        <NlmUniqueID>101291249</NlmUniqueID>
        <ISSNLinking>1933-7191</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000604749">MIRN1323 microRNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C576588">PABPN1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D039122">Poly(A)-Binding Protein I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000072645" MajorTopicYN="Y">Cancer-Associated Fibroblasts</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D039122" MajorTopicYN="N">Poly(A)-Binding Protein I</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cervical cancer</Keyword>
        <Keyword MajorTopicYN="N">GSK-3β</Keyword>
        <Keyword MajorTopicYN="N">IGF2BP1</Keyword>
        <Keyword MajorTopicYN="N">PABPN1</Keyword>
        <Keyword MajorTopicYN="N">Radioresistance</Keyword>
        <Keyword MajorTopicYN="N">miR-1323</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>17</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35334101</ArticleId>
        <ArticleId IdType="doi">10.1007/s43032-021-00820-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s43032-021-00820-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, et al. Cervical cancer: screening, diagnosis and staging. Journal of BUON : official journal of the Balkan Union of Oncology. 2016;21(2):320–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Petry KU. HPV and cervical cancer. Scandinavian journal of clinical and laboratory investigation Supplementum. 2014;244:59-62; discussion. 2014;10(3109/00365513):936683.</Citation>
        </Reference>
        <Reference>
          <Citation>Willmott LJ, Monk BJ. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment. Expert review of anticancer therapy. 2009;9(7):895–903. https://doi.org/10.1586/era.09.58 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/era.09.58</ArticleId>
            <ArticleId IdType="pubmed">19589029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powell ME. Modern radiotherapy and cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(11 Suppl 2):S49–51. https://doi.org/10.1111/igc.0b013e3181f7b241 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/igc.0b013e3181f7b241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C, Lu H, Li J, Xie X, Fan L, Wang D, et al. SOX2 regulates radioresistance in cervical cancer via the hedgehog signaling pathway. Gynecologic oncology. 2018;151(3):533–41. https://doi.org/10.1016/j.ygyno.2018.10.005 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2018.10.005</ArticleId>
            <ArticleId IdType="pubmed">30336948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Zhang Y, Jiang Q. SETD3 reduces KLC4 expression to improve the sensitization of cervical cancer cell to radiotherapy. Biochemical and biophysical research communications. 2019;516(3):619–25. https://doi.org/10.1016/j.bbrc.2019.06.058 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.06.058</ArticleId>
            <ArticleId IdType="pubmed">31235251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandyopadhyay A, Mukherjee U, Ghosh S, Ghosh S, Sarkar SK. Pattern of failure with locally advanced cervical cancer– a retrospective audit and analysis of contributory factors. Asian Pacific Journal of Cancer Prevention : APJCP. 2018;19(1):73–9. https://doi.org/10.22034/apjcp.2018.19.1.73 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.22034/apjcp.2018.19.1.73</ArticleId>
            <ArticleId IdType="pubmed">29373895</ArticleId>
            <ArticleId IdType="pmc">5844639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun FD, Wang PC, Luan RL, Zou SH, Du X. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells. European Review for Medical and Pharmacological Sciences. 2018;22(5):1342–50. https://doi.org/10.26355/eurrev_201803_14476 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26355/eurrev_201803_14476</ArticleId>
            <ArticleId IdType="pubmed">29565492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nahand JS, Taghizadeh-Boroujeni S, Karimzadeh M, Borran S, Pourhanifeh MH, Moghoofei M, et al. microRNAs: new prognostic, diagnostic, and therapeutic biomarkers in cervical cancer. Journal of cellular physiology. 2019;234(10):17064–99. https://doi.org/10.1002/jcp.28457 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.28457</ArticleId>
            <ArticleId IdType="pubmed">30891784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laengsri V, Kerdpin U, Plabplueng C, Treeratanapiboon L, Nuchnoi P. Cervical cancer markers: epigenetics and microRNAs. Laboratory medicine. 2018;49(2):97–111. https://doi.org/10.1093/labmed/lmx080 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/labmed/lmx080</ArticleId>
            <ArticleId IdType="pubmed">29378033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Zhao Y, Xiong W, Ye W, Zhao W, Hua Y. MicroRNA-449a Is downregulated in cervical cancer and inhibits proliferation, migration, and invasion. Oncology research and treatment. 2019;42(11):564–71. https://doi.org/10.1159/000502122 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000502122</ArticleId>
            <ArticleId IdType="pubmed">31578014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua FF, Liu SS, Zhu LH, Wang YH, Liang X, Ma N, et al. MiRNA-338-3p regulates cervical cancer cells proliferation by targeting MACC1 through MAPK signaling pathway. European Review for Medical and Pharmacological Sciences. 2017;21(23):5342–52. https://doi.org/10.26355/eurrev_201712_13919 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26355/eurrev_201712_13919</ArticleId>
            <ArticleId IdType="pubmed">29243777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedroza-Torres A, López-Urrutia E, García-Castillo V, Jacobo-Herrera N, Herrera LA, Peralta-Zaragoza O, et al. MicroRNAs in cervical cancer: evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance. Molecules (Basel, Switzerland). 2014;19(5):6263–81. https://doi.org/10.3390/molecules19056263 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules19056263</ArticleId>
            <ArticleId IdType="pmc">6271743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Li P, Hu J, Zhao LN, Li JP, Ma R, et al. Role and mechanism of miR-4778-3p and its targets NR2C2 and Med19 in cervical cancer radioresistance. Biochemical and biophysical research communications. 2019;508(1):210–6. https://doi.org/10.1016/j.bbrc.2018.11.110 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.11.110</ArticleId>
            <ArticleId IdType="pubmed">30473219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei YQ, Jiao XL, Zhang SY, Xu Y, Li S, Kong BH. MiR-9-5p could promote angiogenesis and radiosensitivity in cervical cancer by targeting SOCS5. European Review for Medical and Pharmacological Sciences. 2019;23(17):7314–26. https://doi.org/10.26355/eurrev_201909_18837 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26355/eurrev_201909_18837</ArticleId>
            <ArticleId IdType="pubmed">31539118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Yang C, Xing Z, Liu P, Zhang B, Ma X, et al. LncRNA GAS5-mediated miR-1323 promotes tumor progression by targeting TP53INP1 in hepatocellular carcinoma. OncoTargets and therapy. 2019;12:4013–23. https://doi.org/10.2147/ott.S209439 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/ott.S209439</ArticleId>
            <ArticleId IdType="pubmed">31190897</ArticleId>
            <ArticleId IdType="pmc">6535457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao H, Zheng C, Wang Y, Hou K, Yang X, Cheng Y, et al. miR-1323 Promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker. Frontiers in oncology. 2020;10:181. https://doi.org/10.3389/fonc.2020.00181 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.00181</ArticleId>
            <ArticleId IdType="pubmed">32154175</ArticleId>
            <ArticleId IdType="pmc">7047338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Liu M. MicroRNA-1323 downregulation promotes migration and invasion of breast cancer cells by targeting tumour protein D52. Journal of biochemistry. 2020;168(1):83–91. https://doi.org/10.1093/jb/mvaa035 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jb/mvaa035</ArticleId>
            <ArticleId IdType="pubmed">32211853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Han W, Ni TT, Lu L, Huang M, Zhang Y, et al. Knockdown of microRNA-1323 restores sensitivity to radiation by suppression of PRKDC activity in radiation-resistant lung cancer cells. Oncology reports. 2015;33(6):2821–8. https://doi.org/10.3892/or.2015.3884 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2015.3884</ArticleId>
            <ArticleId IdType="pubmed">25823795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. Journal of medical genetics. 2015;52(10):710–8. https://doi.org/10.1136/jmedgenet-2015-103334 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmedgenet-2015-103334</ArticleId>
            <ArticleId IdType="pubmed">26358722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F, Ning Z, Ma L, Liu W, Shao C, Shu Y, et al. Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts. Molecular cancer. 2017;16(1):148. https://doi.org/10.1186/s12943-017-0718-4 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-017-0718-4</ArticleId>
            <ArticleId IdType="pubmed">28851377</ArticleId>
            <ArticleId IdType="pmc">5576273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walsh L, Morgia M, Fyles A, Milosevic M. Technological advances in radiotherapy for cervical cancer. Current opinion in oncology. 2011;23(5):512–8. https://doi.org/10.1097/CCO.0b013e3283499d93 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0b013e3283499d93</ArticleId>
            <ArticleId IdType="pubmed">21788897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu TY, Yang JT, Huang TH, Liu HW. Crosstalk with cancer-associated fibroblasts increases the growth and radiation survival of cervical cancer cells. Radiation research. 2014;181(5):540–7. https://doi.org/10.1667/rr13583.1 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1667/rr13583.1</ArticleId>
            <ArticleId IdType="pubmed">24785588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mei Y, Jiang P, Shen N, Fu S, Zhang J. Identification of miRNA-mRNA regulatory network and construction of prognostic signature in cervical cancer. DNA and cell biology. 2020;39(6):1023–40. https://doi.org/10.1089/dna.2020.5452 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/dna.2020.5452</ArticleId>
            <ArticleId IdType="pubmed">32349536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahrami A, Hasanzadeh M, ShahidSales S, Yousefi Z, Kadkhodayan S, Farazestanian M, et al. Clinical significance and prognosis value of Wnt signaling pathway in cervical cancer. Journal of cellular biochemistry. 2017;118(10):3028–33. https://doi.org/10.1002/jcb.25992 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.25992</ArticleId>
            <ArticleId IdType="pubmed">28300286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Zhou H, Zhang G, Xue X. Targeting the canonical Wnt/β-catenin pathway in cancer radioresistance: updates on the molecular mechanisms. Journal of cancer research and therapeutics. 2019;15(2):272–7. https://doi.org/10.4103/jcrt.JCRT_421_18 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/jcrt.JCRT_421_18</ArticleId>
            <ArticleId IdType="pubmed">30964097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. trends in cancer. 2017;3(7):506–28. https://doi.org/10.1016/j.trecan.2017.05.003 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trecan.2017.05.003</ArticleId>
            <ArticleId IdType="pubmed">28718405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X, Zhang H, Guo X, Zhu Z, Cai H, Kong X. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. Journal of hematology &amp; oncology. 2018;11(1):88. https://doi.org/10.1186/s13045-018-0628-y .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-018-0628-y</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
